New hope for transplant patients with advanced skin cancer: immune drugs may control tumors without losing the kidney

NCT ID NCT03816332

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times

Summary

This early-phase study tests whether combining immune-boosting drugs (nivolumab and ipilimumab) with a transplant-protecting drug (tacrolimus) can shrink or control advanced skin cancers in kidney transplant recipients. The goal is to treat the cancer while keeping the donated kidney working. The study involves 12 participants with cancers like melanoma or Merkel cell carcinoma that cannot be surgically removed or have spread.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Moffitt Cancer Center - McKinley Campus

    Tampa, Florida, 33612, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.